(Q59793949)

1

0 references

Johannes M Ludwig

2

0 references

Scott N Gettinger

3

0 references

Hyun S Kim

Journal for Immunotherapy of Cancer

5

0 references

language of work or name

English

0 references

publication date

4 December 2018

5 references

3 November 2019

5 August 2020

9 September 2020

22 November 2020

8 February 2021

5 references

3 November 2019

5 August 2020

9 September 2020

22 November 2020

8 February 2021

6

0 references

issue

1

0 references

page(s)

140

0 references

copyright license

Creative Commons Attribution 4.0 International

5 references

3 November 2019

5 August 2020

9 September 2020

22 November 2020

https://scigraph.springernature.com/pub.10.1186/s40425-018-0458-z

8 February 2021

exact match

0 references

cites work

Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer

1 reference

12 December 2020

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

12 December 2020

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

1 reference

12 December 2020

An immunological approach to ageing

1 reference

12 December 2020

Cancer risk after renal transplantation in the nordic countries, 1964-1986

1 reference

12 December 2020

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

12 December 2020

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1 reference

12 December 2020

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

1 reference

12 December 2020

FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation.

1 reference

12 December 2020

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

1 reference

12 December 2020

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

1 reference

12 December 2020

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

12 December 2020

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

1 reference

12 December 2020

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

12 December 2020

Phagocytosis of microbes: complexity in action

1 reference

12 December 2020

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 December 2020

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

1 reference

12 December 2020

1 reference

12 December 2020

HLA class I antigen loss, tumor immune escape and immune selection

1 reference

12 December 2020

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

1 reference

12 December 2020

In vivo imaging and tumor therapy with the sodium iodide symporter

1 reference

12 December 2020

Immunoregulatory T cells in tumor immunity

1 reference

12 December 2020

The three Es of cancer immunoediting

1 reference

12 December 2020

The immunobiology of cancer immunosurveillance and immunoediting

1 reference

12 December 2020

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

1 reference

12 December 2020

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

1 reference

12 December 2020

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

1 reference

12 December 2020

Image-guided tumor ablation: standardization of terminology and reporting criteria

1 reference

12 December 2020

Non-classical HLA-G antigen and its role in the cancer progression

1 reference

12 December 2020

Permeability properties of tumor surrogate blood vessels induced by VEGF-A.

1 reference

12 December 2020

Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells

1 reference

12 December 2020

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

1 reference

12 December 2020

Cancer immunoediting from immune surveillance to immune escape

1 reference

12 December 2020

Immune surveillance of tumors

1 reference

12 December 2020

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

1 reference

12 December 2020

Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors

1 reference

12 December 2020

Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate

1 reference

12 December 2020

NK cells and cancer immunosurveillance.

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

1 reference

12 December 2020

Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?

1 reference

12 December 2020

Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses

1 reference

12 December 2020

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

1 reference

12 December 2020

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

12 December 2020

Clinical development directions in oncolytic viral therapy

1 reference

12 December 2020

Thunder and lightning: immunotherapy and oncolytic viruses collide

1 reference

12 December 2020

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

1 reference

12 December 2020

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

1 reference

12 December 2020

Viral vector-based therapeutic cancer vaccines

1 reference

12 December 2020

An immune-active tumor microenvironment favors clinical response to ipilimumab

1 reference

12 December 2020

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

1 reference

12 December 2020

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 December 2020

Adoptive immunotherapy for cancer: harnessing the T cell response

1 reference

12 December 2020

Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma

1 reference

12 December 2020

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.

1 reference

12 December 2020

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets

1 reference

12 December 2020

Oncolytic virotherapy

1 reference

12 December 2020

Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

1 reference

12 December 2020

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

1 reference

12 December 2020

Personalized oncology in interventional radiology

1 reference

12 December 2020

Vascular remodeling in cancer.

1 reference

12 December 2020

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

1 reference

12 December 2020

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

12 December 2020

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

1 reference

12 December 2020

Immunotherapy in gastric cancer

1 reference

12 December 2020

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

1 reference

12 December 2020

Going viral with cancer immunotherapy

1 reference

12 December 2020

Genetic evolution of T-cell resistance in the course of melanoma progression

1 reference

12 December 2020

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

1 reference

12 December 2020

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

1 reference

12 December 2020

Oncolytic viruses: a new class of immunotherapy drugs

1 reference

12 December 2020

Current status of immunotherapy

1 reference

12 December 2020

Acquired resistance to immunotherapy and future challenges.

1 reference

12 December 2020

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances

1 reference

12 December 2020

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

1 reference

12 December 2020

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

1 reference

12 December 2020

Coley's Lessons Remembered: Augmenting Mistletoe Therapy

1 reference

12 December 2020

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

1 reference

12 December 2020

Oncolytic Viruses: Therapeutics With an Identity Crisis

1 reference

12 December 2020

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

12 December 2020

Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy

1 reference

12 December 2020

Oncolytic virus therapy for cancer

1 reference

12 December 2020

Harnessing the immune system to improve cancer therapy

1 reference

12 December 2020

Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape

1 reference

12 December 2020

The concept of immune surveillance against tumors. The first theories

1 reference

12 December 2020

Immunotherapy: Powerful combinations

1 reference

12 December 2020

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

1 reference

12 December 2020

Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician

1 reference

12 December 2020

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

1 reference

12 December 2020

Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma

1 reference

12 December 2020

Tissue-resident memory T cells at the center of immunity to solid tumors

1 reference

12 December 2020

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

1 reference

12 December 2020